The Endpoints Slack interview: Cellino CEO Nabiha Saklayen on cell therapy’s future, Elon Musk and time travel

Nabiha Saklayen founded Cellino Biotech just as she was finishing her PhD in physics at Harvard in 2017, while she was still in her 20s.

The startup is trying to create automated ways to produce cell therapies and raised an $80 million Series A round in 2022 to get to work. Endpoints News caught up with Saklayen on how that effort is going, as well as her thoughts on Elon Musk, mission control at Cellino, and even time travel.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Prolonged Treatment for Endometriosis May Harm Live Birth Rate in IVF

DENVER — Two common treatments for advanced stage endometriosis were associated with negative reproductive outcomes for in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI)

October 24, 2024

Health tech funding levels out as startups raise $2.5B in third quarter

Funding for health tech startups might be starting to level out. Digital health startups in the US raised $2.5 billion across 119 deals, according to

October 3, 2023

More restrooms have adult-size changing tables to help people with disabilities

The blue-and-white highway sign for the eastbound rest stop near here displays more than the standard icon of a person in a wheelchair, indicating facilities

October 3, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.